Metagenomi Q2 2026 Earnings Report

Metagenomi EPS Results

• Actual EPS: -$0.73
• Consensus EPS: -$0.55
• Beat/Miss: Missed by -$0.18
• One Year Ago EPS: N/A

Metagenomi Revenue Results

• Actual Revenue: ($0.26) million
• Expected Revenue: $3.01 million
• Beat/Miss: Missed by -$3.27 million
• YoY Revenue Growth: N/A

Metagenomi Announcement Details

• Quarter: Q2 2026
• Date: 8/10/2026
• Time: After Market Closes
• Conference Call Date: Monday, August 10, 2026
• Conference Call Time: 7:00AM ET

Metagenomi (NASDAQ:MGX) (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors. The company works with manufacturers to enhance biofuel production, create greener chemical intermediates and develop more effective formulations for detergents, textiles and crop protection. In the biopharmaceutical realm, Metagenomi’s novel genome-editing components have the potential to drive next-generation gene therapies and precision medicine approaches by enabling targeted modifications in living cells.

Founded in 2019 and headquartered in South San Francisco, Metagenomi has rapidly expanded through strategic collaborations and research partnerships with industry leaders and academic institutions. The company’s management team combines deep expertise in genomics, computational biology and industrial biotechnology, positioning Metagenomi to serve global markets and address growing demand for sustainable, biologically derived solutions. As it advances its pipeline programs and broadens its partner network, Metagenomi continues to pursue breakthrough innovations that bridge metagenomics data with real-world manufacturing needs.